Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug ...

Abercrombie & Fitch reported quarterly earnings of $2.36 per share which beat the analyst consensus estimate of $2.16 per ...

Fintel reports that on November 14, 2025, Jefferies maintained coverage of Abercrombie & Fitch (NYSE:ANF) with a Buy recommendation. Analyst Price Forecast Suggests 61.93% Upside As of November 9, ...

Therapy costs vary widely. In-person therapy in the United States costs an average of $174 per 1-hour session when paid out of pocket, according to a 2023 Milliman report. With commercial health ...

Among dozens of businesses, the company is recognized for safety and construction ANF, a full-service construction and development firm, was honored with two awards at the Associated Builders and ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Abercrombie & Fitch Co. (ANF) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

At 6 a.m. every fall Monday, Kyle Frederick orders two large, iced Americanos at the ground-level coffee shop of his Minneapolis apartment building. “Same order, every time,” he said. “Simplistic.” By ...

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, EMEA and APAC. The Americas ...